This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IDRA Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Idera Pharmaceuticals Stock (NASDAQ:IDRA) 30 days 90 days 365 days Advanced Chart Get Idera Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.17▼$7.2352-Week Range N/AVolume21,870 shsAverage Volume464,030 shsMarket Capitalization$450.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. Read More Receive IDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IDRA Stock News HeadlinesEnergy Recovery Wins “Breakthrough Innovation Award†at IDRA World CongressDecember 16, 2024 | businesswire.comEkso Bionics (NASDAQ: EKSO)April 11, 2024 | fool.comMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia. | The Oxford Club (Ad)Kiniksa PharmaceuticalsNovember 15, 2023 | forbes.comNabriva Therapeutics AG (NBRVF)August 9, 2023 | investing.comMarginaliaApril 26, 2023 | npr.orgNA mysterious rift propels the story in ‘Take What You Need’March 17, 2023 | washingtonpost.comIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic OutlookJanuary 18, 2023 | finanznachrichten.deSee More Headlines IDRA Stock Analysis - Frequently Asked Questions How were Idera Pharmaceuticals' earnings last quarter? Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) posted its earnings results on Monday, November, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. When did Idera Pharmaceuticals' stock split? Shares of Idera Pharmaceuticals split before market open on Friday, November 25th 2022.The 2-1 split was announced on Friday, November 25th 2022. The newly created shares were payable to shareholders after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What other stocks do shareholders of Idera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Idera Pharmaceuticals investors own include BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Sorrento Therapeutics (SRNE), Proteostasis Therapeutics (PTI), Dynavax Technologies (DVAX), Agenus (AGEN) and SCYNEXIS (SCYX). Company Calendar Last Earnings11/08/2021Today8/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IDRA CIK861838 Webwww.iderapharma.com Phone(484) 348-1600Fax617-679-5592Employees32Year Founded1989Profitability EPS (Trailing Twelve Months)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$98.09 million Net MarginsN/A Pretax MarginN/A Return on Equity-68.74% Return on Assets-34.26% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow0.29 Book Value$0.56 per share Price / BookN/AMiscellaneous Outstanding Shares62,355,000Free Float59,206,000Market Cap$450.52 million OptionableOptionable Beta1.25 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:IDRA) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Idera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IDRA Stock Alerts